Literature DB >> 15111148

Effect of prior malignancy on survival after cardiac surgery.

Wilhelm P Mistiaen1, Philip Van Cauwelaert, Philip Muylaert, Floris Wuyts, Fernand Harrisson, Hilde Bortier.   

Abstract

BACKGROUND: The number of patients with a previously treated tumor, needing cardiac surgery is increasing. Whether this operation in these patients is justified is determined by the long-term outcome.
METHODS: Of 8620 patients referred for cardiac surgery, 205 had a documented malignant tumor. The time interval between the occurrence of the tumor and the cardiac surgery was recorded. These patients were matched with 205 patients without a tumor according to age, gender, comorbidity and type of cardiac surgery. The patients were followed retrospectively. A chi(2) Kaplan Meier and Cox' regression analysis were performed.
RESULTS: During follow-up, 95.8% of the patients were traced (2794 patient years). Univariate analysis showed that 5- and 10-year survival was better in patients without a malignant tumor in the history (0.91 +/- 0.02 versus 0.72 +/- 0.03 and 0.73 +/- 0.04 versus 0.40 +/- 0.05; p < 0.0001). For shorter time intervals, mortality for all causes and mortality due to the tumor increase significantly (p < 0.0001). Multivariate analysis identified 4 independent variables: a malignant tumor in the history (p < 0.001), chronic obstructive pulmonary disease (p = 0.003), age (p = 0.001), and impaired left ventricular function (p = 0.035)
CONCLUSIONS: A malignant tumor in the history is the most prognostic factor after cardiac surgery, but the operation is still rewarding. Fatal progression of the tumor is seen if the time interval between the occurrence of the malignant tumor and cardiac surgery is short. Other unfavorable factors are decreased left ventricular function, chronic obstructive pulmonary disease and high age.

Entities:  

Mesh:

Year:  2004        PMID: 15111148     DOI: 10.1016/j.athoracsur.2003.08.049

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  7 in total

1.  Simultaneously performed off-pump coronary artery bypass grafting and colectomy: a case report.

Authors:  Panagiotis Dedeilias; Ioannis Nenekidis; Efstratios Koletsis; Nikolaos G Baikoussis; Panagiotis Hountis; Dimitrios Exarhos; Serafim Klimopoulos
Journal:  World J Surg Oncol       Date:  2010-06-15       Impact factor: 2.754

2.  Cardiac Surgery is Safe in Female Patients with a History of Breast Cancer.

Authors:  Marcus Leistner; Stefanie Sommer; Ivan Aleksić; Christoph Schimmer; Elisa Schmidt-Hengst; Rainer G Leyh; Sebastian-Patrick Sommer
Journal:  Ann Thorac Cardiovasc Surg       Date:  2016-05-13       Impact factor: 1.520

3.  Simultaneous surgery in patients with both cardiac and noncardiac diseases.

Authors:  Yang Yang; Feng Xiao; Jin Wang; Bo Song; Xi-Hui Li; Jian Li; Zhi-Song He; Huan Zhang; Ling Yin
Journal:  Patient Prefer Adherence       Date:  2016-07-18       Impact factor: 2.711

4.  Mortality after transcatheter aortic valve replacement for aortic stenosis among patients with malignancy: a systematic review and meta-analysis.

Authors:  Muhammad Umer Siddiqui; Omar Yacob; Joey Junarta; Ahmed K Pasha; Farouk Mookadam; Mamas A Mamas; David L Fischman
Journal:  BMC Cardiovasc Disord       Date:  2022-05-10       Impact factor: 2.298

5.  Coronary artery bypass grafting in patients with malignancy: a single-institute case series of eight patients.

Authors:  Ming-Kui Zhang; Han-Wen Zhang; Qing-Yu Wu; Hui Xue; Li-Xin Fan
Journal:  BMC Surg       Date:  2022-10-13       Impact factor: 2.030

6.  Simultaneous surgery for obstructive coronary artery disease and ulcerated gastric cancer.

Authors:  F Cantarella; L Graziosi; E Cavazzoni; D Severini; U Da Col; T Ragni; A Donini
Journal:  J Surg Case Rep       Date:  2011-12-01

7.  Cardiopulmonary bypass has a modest association with cancer progression: a retrospective cohort study.

Authors:  Cathy Anne Pinto; Stephen Marcella; David A August; Bart Holland; John B Kostis; Kitaw Demissie
Journal:  BMC Cancer       Date:  2013-11-03       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.